Dr. Jürgen Schnaubelt, Boehringer Ingelheim - Qepler Summits And Conferences

Dr. Jürgen Schnaubelt

Director Early Drug Substance Development
Boehringer Ingelheim
Learn more about Boehringer Ingelheim and why it's one of the world's leading research-driven pharmaceutical companies with 130 years of experience.

Jürgen Schnaubelt graduated in chemistry from the Technical University of Darmstadt and received his PhD in organic chemistry from the Technical University of Dresden. After a postdoctoral stay at the University of Cambridge, he joined Boehringer Ingelheim.

At Boehringer Ingelheim, he held various positions, including process development and R&D project management. In 2021, he was appointed Director Early Drug Substance Development.

Juergen has more than 25 years of professional experience, including HPAPI handling and manufacturing.

Related Sessions:

3rd Annual Highly Potent
APIs Summit 2023

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 22 Feb 2023
  • Virtual,
  • Pharma
Day 1: Wednesday, 22 February 2023
CASE STUDY: HPAPI manufacturing in early Chemical Development
  • Case study on small scale production
  • Feasibility study of new lab facility
View Details
This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookies Policy.